Avastin

Active ingredient
Bevacizumab
Medical indication
Krebs
Pharma Company
Roche Pharma AG/ Roche Deutschland Holding GmbH
Total Number of Doctors1
2,041 doctors
Total Number of Patients2
12,845 patients
Total minimum fees planned3
9,397,100.00 €

Observational Studies including Avastin

Drug No. of doctors1 No. of patients2 Payment per patient3
Avastin n/a n/a n/a Meldung vor Anzeigenpflicht
Avastin 305 n/a 500.00 € 500,00€ für gesamte Dokumentation , 50,00€ pro Zyklus
Avastin 186 1,100 600.00 € ca. 11 Dokumentationen
Avastin 335 3,000 1,260.00 € ca. 30 Dokumentationen
Avastin 275 1,190 790.00 € Baseline: 100€, max. 15 Dokumentationen à 50€, Abschluss: 50€, bis zu 2 Follow-up à 50€
Avastin 122 300 790.00 € 16 Dokumentationen: 1. Ersterfassungsbogen 100,00 € 2. Therapiebogen pro Zyklus 60,00 € 3. Nebenwirkungsbogen pro Zyklus 25,00 € 4. Abschlussbogen 60,00 € 5. Follow-up Bogen 60,00 €
Avastin 123 255 n/a keine Aufwandsentschädigung angegeben
Avastin 370 3,000 900.00 € 100 € pro Dokumentation
Avastin 75 3,000 360.00 € bei vollständiger Dokumentation vo 6 Monaten Behandlungsdauer oder länger im 2.Jahr, ansonsten bei Beobachtungsabschluss innerhalb der ersten 6 Monate des 2.Jahres 180 €
Avastin 250 1,000 n/a keine Aufwandsentschädigung angegeben

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.